Powerful breast-implant testimony constrained by limited evidenceApril 4, 2019Lymphoma & Plasma Cell Disorders
UNITY-NHL: Interim findings show activity, tolerability of umbralisib for R/R MZLApril 2, 2019Lymphoma & Plasma Cell Disorders
Combo could replace standard conditioning regimen for myelomaApril 2, 2019Lymphoma & Plasma Cell Disorders
FDA panel calls for changes to breast implant rupture screeningMarch 27, 2019Lymphoma & Plasma Cell Disorders
FDA panel leans toward more robust breast implant surveillanceMarch 26, 2019Lymphoma & Plasma Cell Disorders
Rituximab boosts survival in primary CNS lymphomaMarch 22, 2019Neuro-oncologyLymphoma & Plasma Cell Disorders
High survival in relapsed FL after primary radiotherapyMarch 21, 2019Follicular LymphomaLymphoma & Plasma Cell Disorders
Worse survival seen among black patients with MCLMarch 20, 2019Lymphoma & Plasma Cell DisordersPatient & Survivor Care
Short telomeres predict poorer response to chemo in CLLMarch 15, 2019Lymphoma & Plasma Cell Disorders
Oral triplet deemed effective in relapsed/refractory myelomaMarch 13, 2019Lymphoma & Plasma Cell Disorders
Therapeutic dosing of busulfan helps reduce relapse in ASCTMarch 13, 2019Lymphoma & Plasma Cell Disorders
Case report may link gluteal implants to lymphomaMarch 12, 2019Lymphoma & Plasma Cell DisordersRare Diseases
